Does Eli Lilly Stock Actually Diversify Your Portfolio?

One of the market’s strongest health care performers barely moves with the index you already own, and that gap is the whole point.

Eli Lilly (LLY) has done what every investor wishes their stocks would do: over the past five trading days it is up about 4.4% while the S&P 500 slipped 0.4%. It has returned about 36% over the past three months and about 50% over the past year, and now trades within about 3% of its 52-week high. If you own it, the urge is to hold tight; if you only watched, the pull is to buy before it gets away. Both instincts answer the wrong question. What decides what this stock does for your money is not where it goes next week, but how much of that return is Eli Lilly’s own story rather than the market you already own through an index fund.

How Much Of Eli Lilly’s Return Is Its Own Story?

Correlation answers that. Over the past five years the stock has moved with the S&P 500 at a correlation of just 0.31, on a scale where 1.0 is perfect lockstep and 0 is no relationship at all. At that level most of what it does has little to do with the broad market you already hold, the mark of a genuine diversifier rather than one more slice of the index in disguise. The independence shows elsewhere too: its correlation to gold is essentially nil at 0.05, and to real estate only 0.25. Over those five years Eli Lilly compounded at about 40% a year, more than three times the S&P 500’s 12.9%, at a higher volatility of 33% against the index’s 17.1%. Adjust for risk and it still leads: its Sharpe ratio, return earned above the risk-free rate per unit of volatility (which is why it runs lower than simply dividing return by volatility), is 1.08 against 0.58 for the index.

Why Eli Lilly Rose With The Market But Barely Fell With It

Correlation tells you how often two things move together, not how hard, and that is where the profile gets interesting. Over the past year, on the days the S&P 500 rose, the stock captured only about 67% of the market’s gain; on the days it fell, it took on just 24% of the loss. It has leaned into the good days more than the bad; that is the asymmetry every holder wants. That is a one-year reading, but beside the low long-run correlation it says something concrete: this stock has added return without a full share of the market’s drawdowns.

Can Rising Volume Keep Outrunning Falling Prices?

That return stream needs a face, and here it is: the obesity and diabetes franchise. In the first quarter of 2026 the company’s total revenue grew 56% year over year, driven largely by that franchise, and management raised full-year 2026 revenue guidance by $2 billion, to as much as $85 billion, about 28% growth over 2025. It also launched Foundayo, a new oral GLP-1 for weight management, widening a market it already leads with Mounjaro. The bear case is not demand but price: the company’s own numbers show U.S. prices fell about 10% year over year excluding a one-time item, and it expects a price headwind in the low-to-mid teens for full-year 2026. So far volume has far outrun the cuts, and the balance between volume and price is what keeps this return going.

A Genuine Diversifier With One Reading To Watch In August

So what role can it play? For a portfolio built mostly on an index fund, Eli Lilly is close to an ideal addition: a strong, market-beating return that arrives largely on its own schedule, with a downside that has bitten less hard than the market’s. Even within the broad health care sector, the honest caveat is not its diversification but its volatility; at 33% it swings more than the index, so the ride is bumpier even when the destination has been better. The reading to watch is whether volume keeps outrunning price when second-quarter 2026 results land on August 5. If you want a sense of how big a swing to expect before you add or trim, that is worth checking first.

Even A Low-Correlation Winner Is Still One Bet

Here is the catch a single great stock cannot solve. Its low correlation makes Eli Lilly a genuine diversifier, but on its own it is still one company, one franchise, one set of risks that move together. A rules-based portfolio spreads those bets across many low-correlation holdings and re-balances on a system, so no single name decides your outcome. That is the difference between owning a good diversifier and a diversified plan. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.